Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

The stock's fall snapped a four-day winning streak.

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

We recently compiled a list of the 14 Best Performing Dividend Stocks To Buy Now. In this article, we are going to take a ...

Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...

Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...

Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.

Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...

Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...

William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...

TSVT gained 5.26% after the company announced a definitive merger agreement with Bristol Myers Squibb BMY. Per the terms of ...

With a volume of 13,248,550, the price of BMY is up 1.71% at $61.21. RSI indicators hint that the underlying stock may be ...